About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main objectives are to improve the diagnosis of immunodeficiencies and autoimmune diseases, addressing also their heterogeneity and mechanisms in close collaboration with the pediatrics, thyroid and systemic disease groups, being internationally recognized in both areas. The group participates in numerous research projects at the Vall d'Hebron Barcelona Hospital Campus that use immunological tests developed for specific projects led by the kidney transplantation, intensive care medicine, internal medicine, allergy and rheumatology groups. During the COVID pandemic the group made contributions in improving the immunogenetic and immunological risk profiles and in the evaluation of the immune response to vaccination and natural infection, collaborating with national and international networks. The group has also generated a biobank of more than 8.000 samples from patients with COVID-19 that have been incorporated into the VHIR biobank.
The group works as a coordinator of the "Focis" Center of Excellence (Federation of Clinical Immunology Societies) of Barcelona.
IP: Pere Soler Palacín Collaborators: Mónica Martínez Gallo, Miriam Gonzalez Amores, Andrea Martín Nalda Funding agency: EUROPEAN COMMISSION Funding: 62500 Reference: RECOMB_H2020SCI2017 Duration: 01/01/2018 - 31/12/2024
IP: - Collaborators: Manuel Hernández González, Rosa Lopez Martinez , Lluis Armadans Gil, Alexandre Martínez Marti, Laia Pinos Tella, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Blanca Borras Bermejo, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil Funding agency: Instituto de Salud Carlos III Funding: 73205 Reference: PI18/01887 Duration: 01/01/2019 - 30/06/2023
IP: Mónica Martínez Gallo Collaborators: Gemma Vila Pijoan, Sandra Salgado Perandres, Adolfo Ruiz Sanmartin, Montserrat Pujol Jover, Estefania Moreno Ruzafa, Jacques Gabriel Rivière Funding agency: Instituto de Salud Carlos III Funding: 117370 Reference: PI18/00346 Duration: 01/01/2019 - 30/06/2023
IP: Pere Soler Palacín Collaborators: Maria Espiau Guarner, Antoni Soriano Arandes, Laura Batlle Masó, Miriam Gonzalez Amores Funding agency: EUROPEAN COMMISSION Funding: 38810 Reference: HITIHE ERASMUS+EAC/A03_2018 Duration: 15/11/2019 - 14/11/2023
The study describes the first documented case worldwide of hereditary angioedema transmission through assisted reproduction.
The paper describes the case of a patient in whom, years after a bone marrow transplant, two immune cell lines corrected the original genetic defect.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
